Board summary
Key figures
47,681
Registered population
55.9% aged 18–64
23.7%
Aged 65+
ICB 19.9% · England 17.9%
3.9%
Ethnic minority (non-White)
1.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 17.1% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,679
Hypertension register
+6.63% in 3 yrs · England +5.60%
339
SMI register
26.2% of Tunbridge Wells'
848
COPD register
Reviews -0.75% in 3 yrs
Forecast to 2030
9,611
Hypertension patients, 2096
+1,932 on today
66.2%
QRISK ≥20% on statins, 2096
+2.80pp over 3 yrs
6.6%
Cancer prevalence, 2096
England 4.5%
Three things the board should see
Heart failure and blood pressure reviews lag.
Heart failure reviews are 59.9% (-8.7% over 2023 to 2025 vs England +8.7%) and under-80 BP control is 62.5% (-5.0% vs England +3.2%).
Asthma annual reviews trail England benchmark.
Annual asthma reviews reach 58.3% (England 65.7%) across 2,937 patients, leaving about 1,200 unreviewed, which may reflect recall gaps to verify locally.
Strong severe mental illness checks and screening.
SMI blood pressure checks reach 90.3% (+11.6 pp over 2023 to 2025 vs England +4.4 pp) alongside 76.8% cervical screening (England 66.8%).
Population, age and ethnicity
An older population with 23.7% aged 65+ may increase complex care requirements
WEALD PCN serves 47,681 registered patients across eight practices. The population is older than benchmarks: 23.7% (11,312 patients) are aged 65+, compared with 20.2% in Tunbridge Wells, 19.9% in NHS Kent and Medway ICB, and 17.9% in England. Working-age adults aged 18–64 represent 55.9% (26,660) and children aged 0–17 comprise 20.4% (9,709). Projected list growth to 2030 is 7.1%, above Tunbridge Wells (5.3%), the ICB (6.0%), and England (2.3%), using unverified methodology. By Census resident data, 96.1% identify as White (Tunbridge Wells 91.5%, ICB 88.6%, England 81.1%), leaving a 3.9% ethnic minority share.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Tunbridge Wells local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Tunbridge Wells LA) | 2,599 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Tunbridge Wells LA) | 1,454 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Tunbridge Wells LA) | 12.4 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
WEALD PCN records 0.0% Core20 patients and an average IMD decile of 5.6
WEALD PCN records 0.0% of its 47,681 registered patients in national IMD quintile 1 (Tunbridge Wells 2.7%, ICB 17.1%, England 21.0%), yielding an estimated Core20 count of 0. Across all eight member practices, both Core20 concentration (0.0% share) and absolute volume (0 patients) reconcile to 0.0% with 0 associated decile 1 or 2 LSOAs. The average IMD decile is 5.6 (Tunbridge Wells 6.8, ICB 5.4, England 5.5). With zero Core20 patients across national deciles 1 and 2, health inequalities initiatives require non-Core20 targeting across vulnerable cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
339
SMI register
0.72% recorded prevalence
208
Learning disability register
0.44% recorded prevalence
17
Care homes, 577 beds
In the PCN catchment
7.9%
Provide unpaid care
Tunbridge Wells, Census 2021
Recorded learning disability is 0.4% (208 patients) and severe mental illness is 0.7% (339 patients), trailing Tunbridge Wells (0.6% and 1.0%), the ICB (0.6% and 0.9%), and England (0.6% and 1.0%). Catchment care homes total 17 (577 beds), alongside 0.7% Gypsy or Irish Traveller residents (England 0.1%). Crude register differences do not confirm under-detection; clinical audits could verify whether case-finding or demography explains lower recorded rates.
Severe mental illness: physical health checks
Annual SMI checks exceed England for blood pressure (90.3% vs 83.4%) and BMI (89.5% vs 82.1%). However, smoking cessation support fell 3.2 pp over 2023 to 2025 (England +0.1 pp) to 90.7% (England 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,679
Hypertension register
+6.63%
Register growth, 3 yrs
Tunbridge Wells +5.38% · England +5.60%
−3.30pp
BP control, under 80
≤140/90 · −1.43pp aged 80+
+1,932
More patients by 2030
Forecast 9,611 (18.47%)
Hypertension case-finding and control
WEALD PCN records 7,679 hypertension patients (16.2% vs Tunbridge Wells 14.8%, England 15.2%), growing +6.6% over 2023 to 2025 (England +5.6%). Recent blood pressure recording reaches 87.1% (Tunbridge Wells 85.9%, England 90.0%), but treated to target is 66.7% (Tunbridge Wells 65.1%, England 70.3%) and under-80 control fell 5.0% over 2023 to 2025 (England +3.2%) to 62.5% (England 67.8%). Heart failure reviews including functional capacity also fell 8.7% over 2023 to 2025 (England +8.7%) to 59.9% (England 78.5%) across 469 patients. Control and review rates lag England despite register growth, suggesting clinical review and titration protocols warrant priority across practices to close management gaps.
Lipids and statins
For patients with QRISK ≥ 20%, 60.2% receive lipid-lowering therapy (Tunbridge Wells 56.6%, England 63.6%), rising +4.9% over 2023 to 2025 (England +6.2%). Diabetes statin treatment without cardiovascular disease is 71.5% (England 73.2%), falling 3.0% over 2023 to 2025 (England +2.1%). Primary prevention recalls may help address lower coverage among at-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 106,666 | £1.80 | £1.90 | £1.86 | £191,999 |
| Cardiovascular (all), 2025 | 134,257 | £2.86 | £3.57 | £3.33 | £383,975 |
In 2026, the PCN prescribed 106,666 lipid-regulating items at £1.80 per item (Tunbridge Wells £1.73, England £1.86, NHS Kent and Medway ICB £1.90), spending £6,400 less than at England's unit cost. Lower unit costs than England show favorable item expenditure, allowing the PCN to prioritize clinical coverage over formulary switching.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.01%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.10%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.6% (2,937 patients, England 6.6%), but 12-month reviews stand at 58.3% (England 65.7%; 3-year change -0.01% vs England +4.4%), leaving about 1,200 patients without a recorded review. Second-hand smoking recording for asthma patients aged 6–19 is 74.4% (279 patients, England 78.8%). Recorded COPD prevalence is 1.8% (848 patients, England 1.9%), with annual reviews at 69.2% (England 76.4%; 3-year change -0.8% vs England +2.8%). Proactive recall across respiratory registers could help close these review delivery gaps.
Cancer register and children's immunisation
Cancer register prevalence is 5.3% (2,517 patients), above England (3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage is 94.1% at 12 months and 89.6% at 24 months. At age 5, MMR dose 1 achieves 96.1% (above the 95.0% target), but dose 2 is 88.2% (a 7.9 pp dose difference), and 4-in-1 booster coverage is 88.2%. Timely recall between primary and pre-school boosters may help protect herd immunity.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In NHS Kent and Medway ICB, 55.6% of staged cancers were diagnosed at stage 1 or 2 in 2022 (4,661 of 8,384), matching England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Known-stage coverage was 63.6% (8,384 of 13,189 registered cancers), trailing England (67.0%). Reaching the ambition requires about 1,630 extra early diagnoses annually. WEALD PCN records 76.8% cervical screening (England 66.8%) and 70.3% breast screening (England 69.9%), while Old School Surgery fell 11.8% (England -1.0%) over 2023 to 2025 to 72.1%. Maximising screening uptake supports the wider system staging ambition.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Maidstone and Tunbridge Wells NHS Trust met all three captured cancer waiting standards, achieving 87.4% on the 62-day referral to treatment standard (above the 85.0% standard by 2.4 pp), 81.8% on the 28-day faster diagnosis standard (above 75.0% by 6.8 pp), and 98.3% on the 31-day combined treatment standard (above 96.0% by 2.3 pp). Across NHS Kent and Medway Integrated Care Board, 62-day performance was 75.9% (below the 85.0% standard by 9.1 pp). For WEALD PCN's 2,517 cancer register patients, strong local acute compliance suggests timely diagnostic and treatment management once referrals enter secondary care.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | East Sussex Healthcare | Medway | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 84.20 | 77.77 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 98.19 | 99.62 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 67.04 | 81.64 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | East Sussex Healthcare | Medway | England |
|---|---|---|---|---|
| MRI | 0.92 | 6.48 | 0.68 | 21.40 |
| CT | 0.51 | 0.48 | 0.00 | 9.92 |
| Echocardiography | 2.57 | 21.94 | 36.62 | 28.48 |
| Colonoscopy | 19.80 | 0.74 | 1.88 | 30.83 |
| Gastroscopy | 24.03 | 0.31 | 3.32 | 29.02 |
| All 15 DM01 tests | 6.42 | 5.27 | 14.20 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In the Community Services Dataset (Jun 2026 (provisional)), adults aged 65+ accounted for 65.8% of community contacts for borough residents (138,250 of 210,170 contacts), though provider-level activity was not captured. With 23.7% of WEALD PCN's list aged 65+, this pattern points to substantial reliance on community health teams to manage frailty and complex long-term conditions locally.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Orchard End | 87 | 0.0 | 83.6% | 66.0% | 97.1% |
| Old Parsonage | 109 | 0.0 | 86.9% | 76.1% | 96.9% |
| Lamberhurst | 119 | 0.0 | 78.1% | 80.4% | 94.2% |
| Howell Surgery | 102 | 0.0 | 92.4% | 69.5% | 94.0% |
| Marden | 110 | 0.0 | 83.7% | 79.3% | 93.8% |
| Weald View | 109 | 0.0 | 66.1% | 75.4% | 78.8% |
| Yalding | 107 | 0.0 | 54.1% | 70.6% | 74.5% |
| Old School Surgery | 93 | 0.0 | 53.8% | 83.5% | 69.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
WEALD PCN trails England on 14 of 25 trends, led by heart failure
WEALD PCN trails England on 14 of 25 three-year trends (2023 to 2025). The widest relative drops are in heart failure reviews, falling 8.7% (England +8.7%) to 59.9% (England 78.5%), and under-80 hypertension blood pressure control, down 5.0% (England +3.2%) to 62.5% (England 67.8%). Conversely, severe mental illness checks show notable strengths: BMI recording rose 14.3 pp to 89.5% (England +5.1 pp to 82.1%) and blood pressure checks rose 11.6 pp to 90.3% (England +4.4 pp to 83.4%). Prioritising chronic disease recall may help reverse widening clinical delivery lags.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BP control, under 80
Hypertension treated to target
Diabetes statin (no CVD)
Asthma reviews
BMI record (SMI)
Alcohol record (psychosis)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Tunbridge Wells | Asset | PCN | Tunbridge Wells |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (577 beds) | n/a | Schools (catchment) | 74 | n/a |
| Children's centres | 1 | 6 | Places of worship | 89 | 89 |
| Libraries | 6 | 9 | Food banks (VCS) | n/a | 2 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 3 | 5 |
| Children and young people (VCS) | 2 | 2 | Carers support groups (VCS) | n/a | 4 |
| Primary schools (LA maintained) | 27 | 24 | Primary academies | 6 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma 12-month reviews are 58.3% across 2,937 patients (Tunbridge Wells 57.1%, ICB 60.4%, England 65.7%; 3-year change -0.01% vs England +4.4%), leaving about 1,200 unreviewed. For discussion, the PCN could run structured asthma recall using a single template and flexible slots to test whether appointment access explains the gap. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Heart failure and hypertension review
Heart failure reviews are 59.9% of 469 patients (England 78.5%, 3-year change -8.7% vs +8.7%; unadjusted register gap -10 to +55); under-80 BP control is 62.5% (England 67.8%). For discussion, the PCN could establish pharmacist-led recall and titration clinics to test whether review capacity or medicines escalation explains the lag. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia register and care-home audit
Recorded dementia is 0.7% (323 of 47,681 patients) vs England 0.8% and Tunbridge Wells 0.9% (unadjusted gap +50 to +101), while 23.7% (11,312) are aged 65+ (England 17.9%). For discussion, practices could audit records and care-home lists (17 homes, 577 beds) to test whether uncoded diagnoses explain the benchmark gap. Low cost, quick to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Non-Core20 equity focus (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI smoking cessation offer (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control and review audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | Practice |
| Telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Heart failure and hypertension review (p12) | Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Dementia register and care-home audit (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
